aTYR PHARMA INC 8K

aTyr Pharma and Kyorin terminated their collaboration and license agreement for efzofitimod effective July 30, 2026, with all development, IP rights, and regulatory assets reverting to aTyr under a detailed wind‑down and mutual release arrangement.

aTyr Pharma, Inc. and Kyorin Pharmaceutical Co., Ltd. entered into a Termination Agreement effective July 30, 2026, under which they terminate their January 6, 2020 Collaboration and License Agreement and related ancillary clinical, quality, and supply agreements, transition all development activities and regulatory assets for the efzofitimod (KRP‑R120) ‘Reversion Products’ back to aTyr, and grant aTyr broad worldwide, perpetual, royalty‑free licenses to Kyorin Background Technology and exclusive rights to New Kyorin IP and Kyorin’s interest in New Joint IP, along with transfer of Orphan Drug Designation, handover of extensive clinical, CMC, and regulatory documentation, continued temporary sponsorship responsibilities for certain Japanese clinical trials by Kyorin, mutual releases of claims related to the collaboration through the termination date, and confirmation that there are no outstanding development cost payments owed by Kyorin to aTyr.

Filing Facts

CIK

1339970

Ticker

-

Form

8K

Source Type

sec

Accession

0001339970-26-000042

Alert Tier

7